Patient-Focused Listening Sessions For Medicare-Negotiated Drugs: Key Takeaways From Round One
Pink Sheet infographic breaks down the mix of patient advocacy groups, individual patients and clinicians offering input to CMS on the first 10 drugs facing Medicare price negotiation.
You may also be interested in...
The ability for Medicare officials to follow-up on patient testimony could make the sessions more informative. They also don’t all have to be the same.
Could Government Negotiated Prices Curtail Access? PBMs And Potential Perverse Incentives Dominate First Medicare Listening Session
Patients and advocacy groups tell Medicare they want lower cost drugs but are concerned that if government negotiations lower list prices, rebate-focused PBMs may preference higher list-price competitors.
Patient advocates see IRA patient listening sessions as an opening to push CMS to have more conversations on access issues in general, but first they want to work on improving the current process.